RxDoctor Payments Data

Cleo Valdez

Primary Care · Huntsville, ALNPI 1831586098

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,550 of the $13,638 with a category attached, or 70.0%. It is spread thinly across 59 manufacturers, the largest accounting for just 21.3%. Among primary care clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,638in general payments, 2019–2025

Across 415 payments — averaging $32.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sobi, Inc$3K
  • Merck$754
  • Karyopharm Therapeutics Inc.$746
  • Novartis$674
  • AstraZeneca$663
  • Mirati Therapeutics, Inc.$588
  • plus $7K from 53 others

What the payments were for

  • Consulting fees$1,2299%
  • Speaking & faculty fees$2,34017%
  • Travel & lodging$3272%
  • Food & beverage$9,55070%
  • Education$1921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sobi, Inc9$2,909
Merck34$754
Karyopharm Therapeutics Inc.6$746
Novartis34$674
AstraZeneca(2 entities)27$663
Mirati Therapeutics, Inc.2$588
Johnson & Johnson24$572
Seagen Inc.17$504
Incyte Corporation14$468
Daiichi Sankyo Inc.13$438
Sanofi8$411
Pfizer19$356
Bristol Myers Squibb11$300
E.r. Squibb & Sons, L.L.C.18$299
Boehringer Ingelheim12$297
Janssen Scientific Affairs, LLC2$228
Takeda Pharmaceuticals U.S.A., Inc.8$209
AbbVie10$202
Beone Medicines USA, Inc.13$200
GSK8$186
Gilead(2 entities)9$185
Exelixis Inc.8$184
Eisai Inc.8$172
Blueprint Medicines Corporation6$161
Stemline Therapeutics Inc.5$141
Lilly USA, LLC9$140
Genentech USA, Inc.6$106
TG Therapeutics, Inc.1$105
Pharmacyclics LLC, An Abbvie Company6$103
Amgen6$100
Beigene USA, Inc.5$91
Array Biopharma Inc4$83
Jazz Pharmaceuticals Inc.3$83
Ipsen Biopharmaceuticals, Inc3$76
Puma Biotechnology, Inc.4$75
Bayer4$73
Regeneron Healthcare Solutions, Inc.4$71
Pharmaessentia USA Corporation2$60
Astellas Pharma US Inc3$59
Sumitomo Pharma America, Inc.3$56
Genmab U.S., Inc.2$56
Acrotech Biopharma Inc.3$51
AVEO Pharmaceuticals, Inc.2$36
Immunocore Limited1$36
Tersera Therapeutics LLC2$36
Agios Pharmaceuticals, Inc.2$33
Kyowa Kirin, Inc.2$32
Fresenius Kabi USA, LLC2$31
Deciphera Pharmaceuticals Inc.1$27
Myriad Genetic Laboratories, Inc.1$24
Iovance Biotherapeutics, Inc.1$23
Taiho Oncology, Inc.1$18
Myovant Sciences Inc.1$18
Mylan Institutional Inc.1$17
G1 Therapeutics, Inc.1$16
Morphosys, US Inc.1$15
ADC Therapeutics America, Inc.1$14
Clovis Oncology, Inc.1$14
Dova Pharmaceuticals1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,638 in reported general payments places this provider in the 95th percentile of 159 primary care providers in Alabama.

See all primary care providers in Alabama

Medicare billing

Part B allowed, 2024
$25,437
Medicare patients
161
Services billed
292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$36,209
XareltoRivaroxaban11$7,994
Prochlorperazine Maleate25$624
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$533
Morphine Sulfate ErMorphine Sulfate13$463
Ondansetron OdtOndansetron15$420
Dexamethasone16$308
Olanzapine17$284
Hydroxyurea11$268
Prednisone57$261
Oxycodone Hcl11$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$356$36,20959 claims
Johnson & JohnsonXarelto$572$7,99411 claims
Lilly USA, LLCOlanzapine$140$28417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 159 primary care providers in Alabama.

Other primary care in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →